ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.17
-0.08 (-0.97%)
At close: Mar 20, 2026, 4:00 PM EDT
8.31
+0.14 (1.71%)
After-hours: Mar 20, 2026, 7:07 PM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ARS Pharmaceuticals stock has a target of 40, which predicts a 389.60% increase from the current stock price of 8.17.
Price Target: $40 (+389.60%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 4, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for ARS Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +389.60% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +267.20% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +242.72% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +230.48% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +267.20% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
160.77M
from 84.28M
Increased by 90.76%
Revenue Next Year
292.12M
from 160.77M
Increased by 81.70%
EPS This Year
-1.43
from -1.74
EPS Next Year
-0.23
from -1.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 190.7M | 364.2M | |||
| Avg | 160.8M | 292.1M | |||
| Low | 131.6M | 199.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 126.3% | 126.6% | |||
| Avg | 90.8% | 81.7% | |||
| Low | 56.1% | 24.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.97 | 0.22 | |||
| Avg | -1.43 | -0.23 | |||
| Low | -2.08 | -1.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.